Ustekinumab-Induced Fatal Acute Heart Failure in a Young Female: A Case Report

Mahmoud Abdelnabi; Saif ElNawaa; Juthipong Benjanuwattra; Mohamed Elmassry; Nandini Nair

doi:10.14797/mdcvj.1076

Ustekinumab-Induced Fatal Acute Heart Failure in a Young Female: A Case Report

Methodist DeBakey Cardiovascular Journal

Volume 18 (2022): Issue 1

By: Mahmoud Abdelnabi , Saif ElNawaa, Juthipong Benjanuwattra , Mohamed Elmassry and Nandini Nair

Open Access

|Jul 2022

Abstract

Data regarding short- and long-term cardiovascular complications of biological agents is lacking. Herein, the authors reported a case of abrupt onset of acute heart failure induced by ustekinumab treatment for resistant pityriasis rubra pilaris in a young healthy female with no past cardiac history. Although medical management was immediately initiated for cardiogenic shock, the patient passed away.

References

Rawal S, Kianian S, Guo W, et al. Alternative uses of ustekinumab for non-indicated dermatological conditions: a systematic review. Arch Dermatol Res. 2021 Jun 22. doi: 10.1007/s00403-021-02262-7. Online ahead of print.
Open DOI Search in Google Scholar Back to article
Beroukhim K, Danesh M, Nguyen C, Koo J, Leon A. A case report of heart failure after therapy with ustekinumab. J Dermatol Dermatol Surg. 2015 Jul;19(2):117–119. doi: 10.1016/j.jdds.2015.03.003
Open DOI Search in Google Scholar Back to article
Ghosh S, Gensler LS, Yang Z, et al. Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn’s Disease: An Integrated Analysis of Phase II/III Clinical Development Programs. Drug Saf. 2019 Jun;42(6):751–768. doi: 10.1007/s40264-019-00797-3
Open DOI Search in Google Scholar Back to article
Krulig E, Gordon KB. Ustekinumab: an evidence-based review of its effectiveness in the treatment of psoriasis. Core Evid. 2010 Jul 27;5:11–22. doi: 10.2147/ce.s5994
Open DOI Search in Google Scholar Back to article
Taleb S, Tedgui A, Mallat Z. IL-17 and Th17 cells in atherosclerosis: subtle and contextual roles. Arterioscler Thromb Vasc Biol. 2015 Feb;35(2):258–64. doi: 10.1161/ATVBAHA.114.303567
Open DOI Search in Google Scholar Back to article
Poizeau F, Nowak E, Kerbrat S, et al. Association Between Early Severe Cardiovascular Events and the Initiation of Treatment With the Anti-Interleukin 12/23p40 Antibody Ustekinumab. JAMA Dermatol. 2020 Nov 1;156(11):1208–1215. doi: 10.1001/jamadermatol.2020.2977
Open DOI Search in Google Scholar Back to article
Simon T, Taleb S, Danchin N, et al. Circulating levels of interleukin-17 and cardiovascular outcomes in patients with acute myocardial infarction. Eur Heart J. 2013 Feb;34(8):570–7. doi: 10.1093/eurheartj/ehs263
Open DOI Search in Google Scholar Back to article
Savvatis K, Pappritz K, Becher PM, et al. Interleukin-23 deficiency leads to impaired wound healing and adverse prognosis after myocardial infarction. Circ Heart Fail. 2014 Jan;7(1):161–71. doi: 10.1161/CIRCHEARTFAILURE.113.000604
Open DOI Search in Google Scholar Back to article
Langley RG, Lebwohl M, Krueger GG, et al. Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up. Br J Dermatol. 2015;172(5):1371–83. doi: 10.1111/bjd.13469
Open DOI Search in Google Scholar Back to article
de Brito M, Yiu ZZN. Cardiovascular Safety of Biologics Targeting Interleukin (IL)-12 and/or IL-23: What Does the Evidence Say? Am J Clin Dermatol. 2021 Sep;22(5):587–601. doi: 10.1007/s40257-021-00612-9
Open DOI Search in Google Scholar Back to article
Ehealthme.com [Internet]. Mountain View, CA: Ehealthme; c2022. Stelara and Deep venous thrombosis - a phase IV clinical study of FDA data; 2022 Mar 21 [cited 2022 Jun 10]. Available from: https://www.ehealthme.com/ds/stelara/deep-venous-thrombosis/
Search in Google Scholar Back to article
Ikonomidis I, Papadavid E, Makavos G, et al. Lowering Interleukin-12 Activity Improves Myocardial and Vascular Function Compared With Tumor Necrosis Factor-a Antagonism or Cyclosporine in Psoriasis. Circ Cardiovasc Imaging. 2017 Sep 12;10(9): e006283. doi: 10.1161/CIRCIMAGING.117.006283
Open DOI Search in Google Scholar Back to article
Huang J, Zhang W, Zhang CL, Wang L. Interleukin-17 aggravates right ventricular remodeling via activating STAT3 under both normoxia and hypoxia. BMC Cardiovasc Disord. 2021 May 21;21(1):249. doi: 10.1186/s12872-021-02069-4
Open DOI Search in Google Scholar Back to article
Chang SL, Hsiao YW, Tsai YN, et al. Interleukin-17 enhances cardiac ventricular remodeling via activating MAPK pathway in ischemic heart failure. J Mol Cell Cardiol. 2018 Sep;122:69–79. doi: 10.1016/j.yjmcc.2018.08.005
Open DOI Search in Google Scholar Back to article

Articles in this issue

DOI: https://doi.org/10.14797/mdcvj.1076 | Journal eISSN: 1947-6108

Journal RSS Feed

Language: English

Page range: 54 - 58

Submitted on: Dec 30, 2021

Accepted on: May 10, 2022

Published on: Jul 12, 2022

Published by: Houston Methodist DeBakey Heart & Vascular Center

In partnership with: Paradigm Publishing Services

Keywords:

acute heart failure,

ustekinumab,

pityriasis rubra pilaris,

biological agents

© 2022 Mahmoud Abdelnabi, Saif ElNawaa, Juthipong Benjanuwattra, Mohamed Elmassry, Nandini Nair, published by Houston Methodist DeBakey Heart & Vascular Center
This work is licensed under the Creative Commons Attribution-NonCommercial 4.0 License.

Volume 18 (2022): Issue 1